Clinical modifiers for heart failure following myocardial infarction.
Heart failure (HF) is a clinical syndrome that occurs when the ability of the heart to meet the requirements of the body fails. Myocardial infarction (MI) is a common antecedent event that predisposes a patient to HF. Loss of cardiac function following MI occurs in the context of myocyte death and ventricular remodeling. The clinical significance of HF following MI is underscored by the fact that among MI survivors, the risk of death is markedly elevated in those who develop HF compared with those who do not. Various modifying factors associated with the development of HF following MI have been identified. Use of multimodality therapy with improved clinical outcomes for HF has increased the need to specifically identify the failing heart at an earlier stage. The ability to identify heart failure early in its pathogenesis will enable finer risk stratification following MI. This article reviews various risk predictors for the development of HF following MI.
Anavekar
Nandan S
NS
Clinical Pharmacology & Therapeutics, University of Melbourne, Austin Health, Studley Road, Heidelberg 3084, Australia.
Anavekar
Nagesh S
NS
D015415:Biomarkers / Q000097:blood; D016207:Cytokines / Q000097:blood; D004452:Echocardiography; D005080:Exercise Test; D006333:Heart Failure / Q000097:blood / Q000175:diagnosis / Q000209:etiology; D006801:Humans; D009203:Myocardial Infarction / Q000150:complications*; D020097:Natriuretic Peptide, Brain / Q000097:blood; D011379:Prognosis; D012307:Risk Factors; D013318:Stroke Volume / Q000502:physiology; D014336:Troponin / Q000097:blood
D015415:Biomarkers; D016207:Cytokines; D014336:Troponin; D020097:Natriuretic Peptide, Brain